Syneron Medical (ELOS) Receives FDA Approval for Plus
Tweet Send to a FriendGet Alerts ELOS Hot Sheet
Trade ELOS Now!
Syneron Medical Ltd. (NASDAQ: ELOS) has received United States Food and Drug Administration (FDA) clearance for elos Plus™, a next generation multi-platform system featuring the Company's proprietary elos technology. The FDA clearance for elos Plus™ follows on the recent international launch in Europe and Asia.
The new elos Plus™ leverages the Company's proprietary elos® technology of optical energy and bi-polar radiofrequency to provide safe and efficacious treatments.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The new elos Plus™ leverages the Company's proprietary elos® technology of optical energy and bi-polar radiofrequency to provide safe and efficacious treatments.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Syneron Medical Ltd (ELOS) Reports In-Line Q1 EPS
- Celgene (CELG) Granted FDA Priority Review for ABRAXANE sNDA in Advanced Pancreatic Cancer
- Trading Radar for 05/22: Hewlett-Packard (HPQ), Target (TGT), Toll Brothers (TOL), Guess? (GES) Report
Create E-mail Alert Related Categories
FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
